JP2012505403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505403A5 JP2012505403A5 JP2011531031A JP2011531031A JP2012505403A5 JP 2012505403 A5 JP2012505403 A5 JP 2012505403A5 JP 2011531031 A JP2011531031 A JP 2011531031A JP 2011531031 A JP2011531031 A JP 2011531031A JP 2012505403 A5 JP2012505403 A5 JP 2012505403A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- polypeptide
- bcl
- alpha
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- 102000051485 Bcl-2 family Human genes 0.000 claims 8
- 108700038897 Bcl-2 family Proteins 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 230000000861 pro-apoptotic effect Effects 0.000 claims 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 4
- 102100021590 Bcl-2-like protein 10 Human genes 0.000 claims 3
- 101000971082 Homo sapiens Bcl-2-like protein 10 Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N glutamic acid Chemical compound OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- 230000002438 mitochondrial effect Effects 0.000 claims 3
- -1 A1 / Bf1-1 Proteins 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102000003952 Caspase 3 Human genes 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 102100030497 Cytochrome c Human genes 0.000 claims 1
- 108010075031 Cytochromes c Proteins 0.000 claims 1
- 101710175001 E1B protein, small T-antigen Proteins 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 102220361483 c.31A>T Human genes 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 101150039936 ced-9 gene Proteins 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 238000006384 oligomerization reaction Methods 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13690608P | 2008-10-10 | 2008-10-10 | |
| US61/136,906 | 2008-10-10 | ||
| PCT/US2009/005568 WO2010042225A2 (en) | 2008-10-10 | 2009-10-09 | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505403A JP2012505403A (ja) | 2012-03-01 |
| JP2012505403A5 true JP2012505403A5 (enExample) | 2012-11-29 |
| JP6049260B2 JP6049260B2 (ja) | 2016-12-21 |
Family
ID=42101140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531031A Expired - Fee Related JP6049260B2 (ja) | 2008-10-10 | 2009-10-09 | プロアポトーシスｂａｘ及びｂｃｌ−２ポリペプチドの化学モジュレータ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110218155A1 (enExample) |
| EP (2) | EP3401684B1 (enExample) |
| JP (1) | JP6049260B2 (enExample) |
| AU (1) | AU2009302840B2 (enExample) |
| CA (2) | CA2738983C (enExample) |
| WO (1) | WO2010042225A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| WO2008045238A2 (en) * | 2006-10-05 | 2008-04-17 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| JP2011522796A (ja) | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター， インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| EP2396004A4 (en) * | 2009-02-11 | 2012-07-25 | Reaction Biology Corp | SELECTIVE KINASE HEMMER |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| DE102011000207A1 (de) * | 2011-01-18 | 2012-07-19 | Forschungsverbund Berlin E.V. | N-Arylaminomethylenbenzothiophenone als Arzneimittel |
| US8877940B2 (en) | 2011-02-22 | 2014-11-04 | Institut National De La Recherche Scientifique | Antibiotic tolerance inhibitors |
| PT2734510T (pt) | 2011-07-22 | 2019-02-13 | Massachusetts Inst Technology | Ativadores de histona desacetilases de classe i (hdacs) e seus usos |
| CA3173988A1 (en) * | 2011-10-11 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic bax |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| WO2013121428A1 (en) | 2012-02-15 | 2013-08-22 | Carmel-Haifa University Economic Corporation Ltd. | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2015184100A2 (en) | 2014-05-30 | 2015-12-03 | Albert Einstein College Of Medicine, Inc. | Targeting dimerization of bax to modulate bax activity |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| CN111777596A (zh) * | 2014-10-09 | 2020-10-16 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| WO2017044308A1 (en) | 2015-09-10 | 2017-03-16 | Albert Einstein College Of Medicine, Inc. | Synthetic antibodies to bax and uses thereof |
| CN108472298B (zh) | 2015-11-24 | 2021-04-20 | 深圳阿拉丁医疗科技有限公司 | 选择性激酶抑制剂 |
| WO2017172368A1 (en) | 2016-03-31 | 2017-10-05 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CN106106481B (zh) * | 2016-06-16 | 2019-06-28 | 湖北工业大学 | 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法 |
| CN109789127B (zh) | 2016-07-29 | 2022-03-25 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| WO2018170067A1 (en) * | 2017-03-14 | 2018-09-20 | Dana-Farber Cancer Institute, Inc. | Small molecule sensitization of bax activation for induction of cell death |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| BR112020004555A2 (pt) | 2017-09-07 | 2020-09-24 | Fog Pharmaceuticals, Inc. | agentes que modulam funções de beta-catenina e métodos dos mesmos |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| CN108558810B (zh) * | 2018-04-25 | 2021-09-21 | 四川大学 | 具有rock激酶抑制作用的黄酮类衍生物 |
| AU2019326423A1 (en) | 2018-08-20 | 2021-04-08 | Fog Pharmaceuticals, Inc. | Collections of peptides, peptide agents, and methods of use thereof |
| WO2020223609A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Methods and compositions for sensitizing cancer cells to drug-induced apoptosis |
| CN110204511B (zh) * | 2019-06-27 | 2023-04-11 | 南京神奇科技开发有限公司 | 一种麝香草酚氨基醇及其制备方法与应用 |
| WO2021211742A1 (en) * | 2020-04-14 | 2021-10-21 | The General Hospital Corporation | Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction |
| US20230293490A1 (en) * | 2020-08-17 | 2023-09-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Profilin1:actin inhibitor as an anti-angiogenic compound |
| KR102766444B1 (ko) * | 2021-06-28 | 2025-02-11 | 재단법인 대구경북첨단의료산업진흥재단 | 트리아지노인돌 유도체를 유효성분으로 하는 항바이러스제 |
| KR102380934B1 (ko) * | 2021-08-30 | 2022-04-01 | 주식회사 쓰리빌리언 | 병원성 변이를 이용한 단백질의 약물 활성 부위 발굴 시스템 및 방법 |
| CN114315807B (zh) * | 2022-01-05 | 2023-09-15 | 江南大学 | 一种吡啶鎓盐光引发剂及其制备方法和应用 |
| CN120583949A (zh) * | 2022-11-18 | 2025-09-02 | 巴塞罗那大学 | sigma-1受体双重抑制剂和可溶性环氧化物水解酶及其在疼痛治疗中的用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US409A (en) | 1837-09-25 | Improvement in many-chambered fire-arms | ||
| US4584377A (en) | 1983-08-18 | 1986-04-22 | Ss Pharmaceutical Co., Ltd. | Novel Fredericamycin A derivatives |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| NL9001255A (nl) | 1990-06-01 | 1992-01-02 | Shell Int Research | Bereiding van polymeren. |
| US5166208A (en) | 1991-10-09 | 1992-11-24 | Boston College | Fredericamycin A derivatives |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| EP0759090A4 (en) * | 1994-04-13 | 2000-05-24 | Jolla Cancer Res Found | Interaction of proteins involved in a cell death pathway |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5897992A (en) * | 1996-09-27 | 1999-04-27 | Cold Spring Harbor Laboratory | Cell-free assay using oncogene-induced apoptosis in drug-resistant cells |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| WO2001014365A1 (en) * | 1999-08-20 | 2001-03-01 | Fred Hutchinson Cancer Research Center | COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS |
| MXPA02003664A (es) * | 1999-10-22 | 2003-10-14 | Wyeth Corp | Pablo, un polipeptido que interactua con bcl-xl, y usos relacionados con el mismo. |
| AU2003302167A1 (en) * | 2002-12-12 | 2004-06-30 | The Burnham Institute | Conversion of apoptotic proteins |
| WO2004076640A2 (en) * | 2003-02-25 | 2004-09-10 | Ambion, Inc. | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same |
| EP1680443B9 (en) | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| ES2344566T3 (es) * | 2003-12-23 | 2010-08-31 | Santaris Pharma A/S | Compuestos oligomericos para la modulacion de bcl-2. |
| SG169395A1 (en) * | 2006-02-09 | 2011-03-30 | Univ South Florida | Detection of cancer by elevated levels of bcl-2 |
-
2009
- 2009-10-09 EP EP17210306.1A patent/EP3401684B1/en not_active Not-in-force
- 2009-10-09 CA CA2738983A patent/CA2738983C/en active Active
- 2009-10-09 CA CA2999537A patent/CA2999537C/en active Active
- 2009-10-09 JP JP2011531031A patent/JP6049260B2/ja not_active Expired - Fee Related
- 2009-10-09 AU AU2009302840A patent/AU2009302840B2/en not_active Ceased
- 2009-10-09 WO PCT/US2009/005568 patent/WO2010042225A2/en not_active Ceased
- 2009-10-09 EP EP09819587.8A patent/EP2338056B1/en not_active Not-in-force
- 2009-10-09 US US13/123,645 patent/US20110218155A1/en not_active Abandoned
-
2014
- 2014-10-10 US US14/512,131 patent/US20160171150A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schmitz et al. | Structural and functional analysis of the NF-kappa B p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an alpha-helical conformation. | |
| Walensky et al. | Hydrocarbon-stapled peptides: principles, practice, and progress: miniperspective | |
| Zhan et al. | An ultrahigh affinity d-peptide antagonist Of MDM2 | |
| Long et al. | Design of Cell-Permeable Stapled Peptides as HIV‑1 Integrase Inhibitors | |
| Li et al. | Apamin as a novel template for structure-based rational design of potent peptide activators of p53 | |
| Budhidarmo et al. | IAPs: Modular regulators of cell signalling | |
| JP6265583B2 (ja) | 生理活性アルファベータペプチドを作製する方法 | |
| JP2008536483A5 (enExample) | ||
| US20130157942A1 (en) | Stabilized insulinotropic peptides and methods of use | |
| US20160333049A1 (en) | Peptidomimetic macrocycles and uses thereof | |
| Estieu-Gionnet et al. | Stabilized helical peptides: overview of the technologies and therapeutic promises | |
| WO2007030804A1 (en) | Prion-specific peptoid reagents | |
| WO2023274347A1 (zh) | 以细胞穿膜肽介导的多肽或微蛋白靶向嵌合物的模块化组装技术及其应用 | |
| Nair et al. | Structural aspects of interactions within the Myc/Max/Mad network | |
| JPH03275699A (ja) | 新規なペプチド | |
| WO2016171980A1 (en) | Polypeptides targeting hiv fusion | |
| Cai et al. | HBx-derived constrained peptides inhibit the secretion of hepatitis B virus antigens | |
| US20200360529A1 (en) | Peptidic materials that traffic efficiently to the cell cytosol and nucleus | |
| CA3213057A1 (en) | Use of adnf polypeptides in therapy | |
| Nery et al. | Evidence for the interaction of the regulatory protein Ki-1/57 with p53 and its interacting proteins | |
| Malcikova et al. | Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. | |
| US20220340629A1 (en) | Myosin Derived Peptides and Related Compounds with Anticoagulant Activities | |
| Reynolds et al. | Peptide fragments of a β-defensin derivative with potent bactericidal activity | |
| Jurkova et al. | Human cyclophilins—an emerging class of drug targets | |
| Frankel | The importance of being flexible. |